斯诺RNAs U34 和 U35a:状细胞疾病并发症的新目标
Waseem Chauhan1, Sudharshan Setra Janardhana Shetty1, Shirin Ferdowsi1
1Department of Physiology, University of Tennessee Health Science Center, Memphis.
Circulation research
|May 15, 2025
概括
研究人员发现,Rpl13a小核子RNAs (snoRNAs) U34和U35a在状细胞疾病 (SCD) 红细胞中增加反应性氧物种 (ROS). 将这些snoRNA与反感性寡核酸向改善了小鼠中与SCD相关的条件.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 状细胞疾病 (SCD) 的特征是红细胞反应性氧物种 (ROS) 和氧化应激,有助于血管封闭.
- 来自Rpl13a位点的小型非编码核核基RNA (snoRNA) 是已知的ROS调节器,但它们在SCD中的作用尚不清楚.
研究的目的:
- 调查状红细胞 (RBC) 中Rpl13asnoRNAs的存在和功能.
- 为了确定Rpl13a的snoRNA是否调节ROS水平并对SCD病理生理学作出贡献.
- 阐明snoRNA介导的ROS调节机制及其对SCD血动力学的影响.
主要方法:
- 使用人类红细胞和Rpl13asnoRNA淘汰状小鼠.
- 使用CRISPR-Cas9基因组编辑来产生特定的snoRNA淘汰细胞系 (U32a,U33,U34,U35a,U25).
- 用于在体内基因向的反感性寡核酸.
主要成果:
- 升高的Rpl13asnoRNAs (U32a,U33,U34,U35a) 与状红细胞中的ROS增加相关.
- U32a,U34和U35a通过影响过氧化酶活性来调节ROS和过氧化,特别是通过Prdx2mRNA的2'-O-甲基化 (U32a,U34) 和独立的机制 (U35a).
- 在状小鼠体内准U34+U35a或U32a+U34+U35a显著降低了ROS,改善了红色素形成和贫血,缓解了炎症和内皮损伤,减少了血管封闭,降低了死亡率.
结论:
- Rpl13a 斯诺RNAs U34 和 U35a 通过调节 Prdx2 对血动力学产生影响,从而加剧状红色素细胞中的 ROS 水平.
- 针对U34和U35a的反感性寡核酸体显示出作为SCD的新治疗策略的希望.
相关概念视频
Alternative RNA Splicing
20.5K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
20.5K
iPS Cell Differentiation
2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121


